Document:

Exhibit
10.3

 

THE
ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A)
AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL IN
A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER
SAID ACT. 

 

	Principal
    Amount: USD $40,000	Issue
    Date: September 12th, 2022	
	 	Maturity
    Date: March 12th, 2023	

 

PROMISSORY
NOTE

 

FOR
VALUE RECEIVED, pursuant to the terms of this Promissory Note (this “Note”) Nutralife Biosciences, Inc., a Florida corporation
(the “Company”), hereby promises to pay to the order of Green Dynamics, LLC a Florida
limited liability Corporation, with an address at 7050 west Palmetto Park Rd. Suite
510 Boca Raton FL. 33431 (the “Holder”) the sum of the Principal Amount as set forth above (the “Principal Amount”)
together with any interest as set forth herein, on the dates as set forth herein, and to pay interest on the unpaid principal balance
hereof at the rate of 20% annually 10% (the “Interest Rate”) over the six month term, simple interest, from
the Issue Date as set forth above (the “Issue Date”) until the same becomes due and payable, whether by payment as set forth
herein, at maturity or by prepayment or otherwise.

 

This
Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive
rights or other similar rights of members of the Company and will not impose personal liability upon the holder thereof.

 

The
following additional terms shall apply to this Note:

 

Article
I. GENERAL TERMS

 

Section
I.01 Interest; Payments; Prepayment.

 

		(a)	Interest
                                            shall commence accruing on the Issue Date at the Interest Rate and shall be computed at the
                                            rate of 20% annually 10% (the “Interest Rate”) over the six month
                                            term, and the actual number of days elapsed.
	 	 	 
		(b)	Unless
                                            earlier accelerated by the Holder upon the occurrence of an Event of Default (as defined
                                            below), the principal of this Note and all accrued unpaid interest will be due and payable
                                            by the Company on the first anniversary of the issue date on the face of this Note (the “Maturity
                                            Date”).
	 	 	 
		(c)	All
                                            payments due hereunder shall be made in lawful money of the United States of America. All
                                            payments shall be made at the address of the Holder as set forth in the Purchase Agreement,
                                            or via wire transfer instructions as the Holder shall hereafter give to the Company by written
                                            notice made in accordance with the provisions of the Purchase Agreement.

 

    	1

    	 

    

 

		(d)	Whenever
                                            any amount expressed to be due by the terms of this Note is due on any day which is not a
                                            Business Day, the same shall instead be due on the next succeeding day which is a Business
                                            Day and, in the case of any interest payment date which is not the date on which this Note
                                            is paid in full, the extension of the due date thereof shall not be taken into account for
                                            purposes of determining the amount of interest due on such date.
	 	 	 
		(e)	The
                                            Company may prepay all or any portion of the Principal Amount and any accrued and unpaid
                                            interest and any and all other amounts that may be due and payable to the Holder hereunder
                                            (collectively, the “Indebtedness”) at any time.

 

Section
I.02 Events of Default. If any of the following events set forth in this Section I.02 occur, it shall be an “Event of Default”
hereunder:

 

		(a)	Failure
                                            to Pay Principal or Interest. The Company fails to pay the principal hereof or interest
                                            thereon when due on this Note, whether at maturity, upon acceleration or otherwise, and such
                                            failure has not been cured within five (5) days of notice thereof from the Holder to the
                                            Company.
	 	 	 
		(b)	Breach
                                            of Covenants. The Company breaches any covenant or other term or condition contained
                                            in this Note, and such breach has not been cured within five (5) days of notice thereof from
                                            the Holder to the Company.
	 	 	 
		(c)	Receiver
                                            or Trustee. The Company shall (i) apply for or consent to the appointment of, or the
                                            taking of possession by, a receiver, custodian, trustee or liquidator; (ii) make a general
                                            assignment for the benefit of the Company’s creditors; or (iii) commence a voluntary
                                            case under the U.S. Bankruptcy Code as now and hereafter in effect, or any successor statute.
	 	 	 
		(d)	Bankruptcy
                                            Proceedings: A proceeding or case shall be commenced, without the application or consent
                                            of the Company, in any court of competent jurisdiction, seeking (1) liquidation, reorganization
                                            or other relief with respect to it or its assets or the composition or readjustment of its
                                            debts, or (2) the appointment of a trustee, receiver, custodian, liquidator or the like of
                                            any substantial part of its assets, and, in each case, such proceedings or case shall continue
                                            undismissed, or an order, judgment or decree approving or ordering any of the foregoing shall
                                            be entered and continue unstayed and in effect, for a period of 60 days, if in the United
                                            States, or 90 days, if outside of the United States; or an order for relief against the Company
                                            shall be entered in an involuntary case under any bankruptcy, insolvency, composition, readjustment
                                            of debt, liquidation of assets or similar Law of any jurisdiction.

 

    	2

    	 

    

 

		(e)	Change
                                            of Control. There occurs a Change of Control (as defined below) of the Company, or the
                                            Company enters into any agreement which could reasonably be expected to result in a Change
                                            of Control. For purposes herein, “Change of Control” means the occurrence of
                                            any of the following events:

 

		(i)	Change
                                            in Ownership of the Company. A change in the ownership of the Company which occurs on
                                            the date that any one person, or more than one person acting as a group (“Person”),
                                            acquires ownership of the stock of the Company that, together with the stock held by such
                                            Person, constitutes more than fifty percent (50%) of the total voting power of the stock
                                            of the Company; provided, however, that for purposes of this Section I.02(e)(i), the acquisition
                                            of additional stock by any one Person, who is considered to own more than fifty percent (50%)
                                            of the total voting power of the stock of the Company prior to such transaction will not
                                            be considered a Change in Control. Further, if the shareholders of the Company immediately
                                            before such change in ownership continue to retain after the change in ownership, in substantially
                                            the same proportions as their ownership of shares of the Company’s voting stock prior
                                            to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%)
                                            or more of the total voting power of the stock of the Company or of the ultimate parent entity
                                            of the Company, such event shall not be considered a Change in Control under this Section
                                            I.02(e)(i). For this purpose, indirect beneficial ownership shall include, without limitation,
                                            an interest resulting from ownership of the voting securities of one or more corporations
                                            or other business entities which own the Company, as the case may be, either directly or
                                            through one or more subsidiary corporations or other business entities.
	 	 	 
		(ii)	Change
                                            in Effective Control of the Company. A change in the effective control of the Company
                                            which occurs on the date that a majority of members of the Board of Directors of the Company
                                            (the “Board”) is replaced during any twelve (12) month period by Directors whose
                                            appointment or election is not endorsed by a majority of the members of the Board prior to
                                            the date of the appointment or election. For purposes of this Section I.02(e)(ii), if any
                                            Person is considered to be in effective control of the Company, the acquisition of additional
                                            control of the Company by the same Person will not be considered a Change in Control.
	 	 	 
		(iii)	Change
                                            in Ownership of a Substantial Portion of the Company’s Assets. A change in the
                                            ownership of a substantial portion of the Company’s assets which occurs on the date
                                            that any Person acquires (or has acquired during the twelve (12) month period ending on the
                                            date of the most recent acquisition by such person or persons) assets from the Company that
                                            have a total gross fair market value equal to or more than fifty percent (50%) of the total
                                            gross fair market value of all of the assets of the Company immediately prior to such acquisition
                                            or acquisitions. For purposes of this Section I.02(e)(iii), gross fair market value means
                                            the value of the assets of the Company, or the value of the assets being disposed of, determined
                                            without regard to any liabilities associated with such assets.
	 	 	 
		(iv)	Merger
                                            or Consolidation. The Company or its shareholders is or are party(ies) to a merger, consolidation
                                            or similar transaction where the Company is not the surviving entity.

 

    	3

    	 

    

 

Section
I.03 Effects of an Event of Default.

 

		(a)	Upon
                                            the occurrence of any Event of Default exercisable through the delivery of written notice
                                            to the Company by such Holder (the “Default Notice”), this Note shall become
                                            immediately due and payable and the Company shall pay to the Holder, within five (5) Business
                                            Days of the date of the Event of Default (the “Mandatory Prepayment Date”), all
                                            of the Indebtedness in full, together with any and all other amounts payable hereunder (collectively,
                                            the “Default Amount”), all without demand, presentment or notice, all of which
                                            hereby are expressly waived, together with all costs, including, without limitation, legal
                                            fees and expenses, of collection, and the Holder shall be entitled to exercise all other
                                            rights and remedies available at law or in equity.
	 	 	 
		(b)	If
                                            the Company fails to pay the Default Amount by the “Mandatory Prepayment Date”
                                            then the Holder shall have the right at any time to pursue any legal and equitable remedies
                                            and rights of the Holder pursuant to this Note and under all applicable laws.

 

Section
I.04 Trigger Events. The Company waives presentment, demand for performance, notice of nonperformance, protest, notice of protest
and notice of dishonor, except as expressly stated herein.

 

Section
I.05 Negative Covenants. During the term this Note remains outstanding, unless the Holder shall have otherwise given prior written
consent, the Company shall not, directly or indirectly:

 

		(a)	amend
                                            its charter documents in any manner that does or could reasonably be expect to materially
                                            and adversely affects any rights of the Holder;
	 	 	 
		(b)	repay,
                                            repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number
                                            of shares of its common stock or other equity securities;
	 	 	 
		(c)	use
                                            the proceeds from this Note for any purpose other than the Company’s working capital,
                                            production of the Company’s existing inventory of goods for sale to the public, or
                                            product development, without the express written consent of the Holder; or
	 	 	 
		(d)	enter
                                            into any agreement with respect to any of the foregoing.

 

Section
I.06 Taxes. The Company agrees to pay upon issuance of this Note, all intangible taxes due under Florida law as result of this
Note.

 

Article
II. MISCELLANEOUS

 

Section
II.01 Failure or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or privilege
hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude
other or further exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative
to, and not exclusive of, any rights or remedies otherwise available.

 

    	4

    	 

    

 

Section
II.02 Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall
be in writing and shall be given in accordance with the provisions of the Purchase Agreement.

 

Section
II.03 Amendments. This Note and any provision hereof may only be amended by an instrument in writing signed by the Company and
the Holder. The term “Note” and all reference thereto, as used throughout this instrument, shall mean this instrument as
originally executed, or if later amended or supplemented, then as so amended or supplemented.

 

Section
II.04 Assignability. This Note shall be binding upon the Company and its permitted successors and permitted assigns, and shall
inure to be the benefit of the Holder and its successors and assigns. The Company may not assign or transfer this Note or any right,
title or interest herein, whether voluntarily or by operation of law, without the prior written consent of the Holder, and any purported
assignment or transfer without such consent shall be null and void and of no force or effect.

 

Section
II.05 Costs and Costs of Collection. If default is made in the payment of this Note, the Company shall pay the Holder hereof costs
of collection, including reasonable attorneys’ fees.

 

Section
II.06 Governing Law. This Note shall be governed by, enforced, and construed under and in accordance with the Laws of the State
of Florida, without giving effect to the principles of conflicts of law thereunder. Each of the Parties irrevocably consents and agrees
that any legal or equitable action or proceedings arising under or in connection with this Agreement shall be brought exclusively in
the courts of the State of Florida or the federal courts of the United States, in each case located in Broward County, Florida. By execution
and delivery of this Note, each Party irrevocably submits to and accepts, with respect to any such action or proceeding, generally and
unconditionally, the jurisdiction of the aforesaid courts, and irrevocably waives any and all rights such Party may now or hereafter
have to object to such jurisdiction

 

Section
II.07 Usury Savings Clause. Notwithstanding any provision in this Note to the contrary, the total liability for payments of interest
and payments in the nature of interest, including, without limitation, all charges, fees, exactions, or other sums which may at any time
be deemed to be interest, shall not exceed the limit imposed by the usury laws of the jurisdiction governing this Note or any other applicable
law. In the event the total liability of payments of interest and payments in the nature of interest, including, without limitation,
all charges, fees, exactions or other sums which may at any time be deemed to be interest, shall, for any reason whatsoever, result in
an effective rate of interest, which for any month or other interest payment period exceeds the limit imposed by the usury laws of the
jurisdiction governing this Note, all sums in excess of those lawfully collectible as interest for the period in question shall, without
further agreement or notice by, between, or to any party hereto, be applied to the reduction of the outstanding principal balance due
hereunder immediately upon receipt of such sums by the Holder hereof, with the same force and effect as though the Company had specifically
designated such excess sums to be so applied to the reduction of the principal balance then outstanding, and the Holder hereof had agreed
to accept such sums as a penalty-free payment of principal; provided, however, that the Holder may, at any time and from time to time,
elect, by notice in writing to the Company, to waive, reduce, or limit the collection of any sums in excess of those lawfully collectible
as interest, rather than accept such sums as a prepayment of the principal balance then outstanding. It is the intention of the parties
that the Company does not intend or expect to pay, nor does the Holder intend or expect to charge or collect any interest under this
Note greater than the highest non-usurious rate of interest which may be charged under applicable law.

 

    	5

    	 

    

 

Article
III.

 

It
is agreed that this note will serve as a bridge note financing loan and can, and will be paid in full before the maturity date above
in the event that the Compay has any remuneration, income or capital raise from any other source.

 

NLBS
DEPOSIT ADVICE

 

	Bank
    Name:	TRUIST
	 	 
	Account
    Name:	NutraLife
    Biosciences, Inc.
	 	 
	Swift
    Code:	BRBTUS33
	 	 
	Routing
    #:	263191387
	 	 
	Account#:	1100019240027
	 	 
	Bank
    Phone #: 	(800)
    226-5228
	 	 
	Bank
    Address: 	300
    S Pine Island Rd, Plantation, FL 33324

 

[SIGNATURE
PAGE FOLLOWS]

 

    	6

    	 

    

 

IN
WITNESS WHEREOF, the Company and the Holder have caused this Note to be signed as of the Issue Date.

 

	 	For
    Nutralife Biosciences, Inc.:
	 	 	 
	 	By:	/s/
    Edgar Ward
	 	Name:	Edgar
    Ward 
	 	Title:	Chief
    Executive Officer

 

    	7Exhibit
10.4

 

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

Nutralife
Biosciences, Inc.

	Warrant
    Shares: 5,000,000	Issue
    Date: September 12th, 2022

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that for the value received, Green Dynamics, LLC (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the Issue Date as set forth above (the “Issue Date”) and on or prior to 5:00 p.m. (New York City time) on the second anniversary
of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Nutralife Biosciences,
Inc., a Florida corporation (the “Company”), up to the number of shares set forth above (as subject to adjustment hereunder,
the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal
to the Exercise Price, as defined in Section 2(b), subject to adjustment as set forth herein.

 

Section
1.  Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Note Exchange Agreement (the “Agreement”), dated as of the Issue Date, among the Company and the Holder. This Warrant is
subject to the terms and conditions of the Agreement, and in the event of a conflict between the Agreement and this Warrant, the terms
and conditions of this Warrant shall control. In addition, for purposes herein:

 

(a)
The Company and the Holder may be referred to herein individually as a “Party” and collectively as the “Parties.”

 

(b)
“Person” means any individual, sole proprietorship, partnership, limited liability company, corporation, joint venture, trust,
incorporated organization or government or department or agency thereof.

 

(c)
“Transfer Agent” means the Company’s transfer agent for the Common Stock as in place from time to time.

 

    	 

    	 

    

 

Section
2.  Exercise.

 

(a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Issue Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail with return receipt requested (or e-mail attachment to an e-mail with return receipt requested) of the
Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days
(as defined below) and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(f)(i)) following
the date of exercise as aforesaid, the Holder shall deliver to the Company the aggregate Exercise Price for the shares specified in the
applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure
specified in Section 2(c) is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor
shall any medallion guarantee (or other types of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has exercised
the rights to purchase all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder
shall surrender this Warrant to the Company for cancellation together with the final Notice of Exercise as delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases, and the records of the Company shall be deemed controlling in the absence of manifest error. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this Section 2(a), following the purchase of a
portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less
than the amount stated on the face hereof.

 

(b)
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $0.08, subject to adjustment hereunder
(the “Exercise Price”).

 

    	2

    	 

    

 

(c)
Cashless Exercise. In the event that (1) the Warrant Shares are not registered for resale pursuant to a registration statement
under the Securities Act of 1933, as amended (the “Securities Act”) as of the date of the delivery of a Notice of Exercise
and (2) the Market Price (as defined below) of one share of Common Stock is greater than the Exercise Price in effect at such time, then
this Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder
shall be entitled to receive a number of Warrant Shares computed using the following formula:

 

	 	X	=	Y(A-B)	 
	 	 	 	A	 

 

	 	Where:	 	 
	 	 	 	 
	 	X
    	=
    	The
    number of Warrant Shares to be issued to Holder
	 	 	 	 
	 	Y	=	the
    number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such calculation)
	 	 	 	 
	 	A	=	the
    Market Price (at the date of such calculation)
	 	 	 	 
	 	B
    	=	the
    Exercise Price (as adjusted to the date of such calculation)

 

(d)
Characteristics. If Warrant Shares are issued in such a cashless exercise, the Parties acknowledge and agree that in accordance
with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and
the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not
to take any position contrary to this Section 2(d).

 

(e)
Market Price. “Market Price” for the Common Stock (or any replacement security pursuant to Section 3(b)) means, for
any security as of any date, the first of the following which shall apply:

 

		(i)	the
                                            dollar volume-weighted average price for such security on the OTC Markets or a United States
                                            national securities exchange which is the principal market on which such security is then
                                            traded (as applicable, the “Trading Market”) during the period beginning at 9:30:01
                                            a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg
                                            L.P. through its “HP” function (set to weighted average) or, if the foregoing
                                            does not apply, the dollar volume-weighted average price of such security in the over-the-counter
                                            market on the electronic bulletin board for such security during the period beginning at
                                            9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg
                                            L.P.;
	 	 	 
		(ii)	if
                                            no dollar volume-weighted average price is reported for such security by Bloomberg L.P. for
                                            such hours as set forth in Section 2(e)(i), the average of the highest closing bid price
                                            and the lowest closing ask price of any of the market makers for such security as reported
                                            in the “pink sheets” by OTC Markets Group Inc. (formerly Pink Sheets LLC); and
	 	 	 
		(iii)	if
                                            the Market Price cannot be calculated for such security on such date on bases as set forth
                                            in Section 2(e)(i) or Section 2(e)(ii), the Market Price of such security on such date shall
                                            be the fair market value of such security as mutually determined in good faith by the Board
                                            of Directors of the Company and the Holder after taking into consideration factors they may
                                            each deem appropriate.

 

    	3

    	 

    

 

(f)
Mechanics of Exercise.

 

		(i)	Delivery
                                            of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased
                                            hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account
                                            of the Holder’s or its designee’s balance account with The Depository Trust Company
                                            through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company
                                            is then a participant in such system and either (A) there is an effective registration statement
                                            permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder
                                            or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale
                                            limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise
                                            by physical delivery of a certificate, registered in the Company’s share register in
                                            the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
                                            is entitled pursuant to such exercise to the address specified by the Holder in the Notice
                                            of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery
                                            to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
                                            aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the
                                            Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such
                                            date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise,
                                            the Holder shall be deemed for all corporate purposes to have become the holder of record
                                            of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
                                            of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
                                            Price (other than in the case of a cashless exercise) is received within the earlier of (i)
                                            two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
                                            Period following delivery of the Notice of Exercise. The Company agrees to maintain a transfer
                                            agent that is a participant in the FAST program so long as this Warrant remains outstanding
                                            and exercisable. As used herein, “Standard Settlement Period” means the standard
                                            settlement period, expressed in a number of Trading Days, on the Company’s primary
                                            Trading Market with respect to the Common Stock as in effect on the date of delivery of the
                                            Notice of Exercise. For purposes herein, “Trading Day” means any day on which
                                            the Common Stock (or any replacement security pursuant to Section 3(b)) is traded on the
                                            Trading Market or is otherwise reported on “pink sheets” by OTC Markets Group
                                            Inc. (formerly Pink Sheets LLC) or a similar organization or agency succeeding to its functions
                                            of reporting prices.
	 	 	 
		(ii)	Delivery
                                            of New Warrants Upon Partial Exercise. If this Warrant shall have been exercised in part,
                                            the Company shall, at the request of a Holder and upon surrender of this Warrant certificate,
                                            at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
                                            the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant,
                                            which new Warrant shall in all other respects be identical with this Warrant.
	 	 	 
		(iii)	No
                                            Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares
                                            shall be issued upon the exercise of this Warrant. As to any fraction of a share which the
                                            Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at
                                            its election, either pay a cash adjustment in respect of such final fraction in an amount
                                            equal to such fraction multiplied by the Exercise Price or round up to the next whole share.
	 	 	 
		(iv)	Charges,
                                            Taxes, and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder
                                            for any issue or transfer tax or other incidental expense of the Company in respect of the
                                            issuance of such Warrant Shares, all of which taxes and Company expenses shall be paid by
                                            the Company, and such Warrant Shares shall be issued in the name of the Holder or in such
                                            name or names as may be directed by the Holder; provided, however, that, in the event that
                                            Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
                                            when surrendered for exercise shall be accompanied by the Assignment Form attached hereto
                                            duly executed by the Holder and the Company may require, as a condition thereto, the payment
                                            of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
                                            shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise
                                            and all fees to the Depository Trust Company (or another established clearing corporation
                                            performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

    	4

    	 

    

 

(g)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and the Holder shall not have
the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and
any other Person acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution
Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing
sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include
the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made but
shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of
this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the
unexercised or non-converted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents)
subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any
of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(g), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder,
it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section
13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the
extent that the limitation contained in this Section 2(g) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to
any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(g), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report
filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice
by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request
of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be
4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(g), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section 2(g) shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this Section 2(g)
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(g) to correct this
Section 2(g) (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this Section 2(g) shall apply to a successor holder of this Warrant.

 

    	5

    	 

    

 

Section
3.  Certain Adjustments.

 

(a)
Equitable Adjustments. The Exercise Price shall be subject to further equitable adjustments as described in this Section 3, for
additional stock splits, stock dividends or rights offerings affecting the Common Stock of the Company and relating to the Company’s
securities, combinations, recapitalization, reclassifications, extraordinary distributions and similar events that occur on or after
the determination of the Exercise Price. By way of example and not limitation, (i) in the event that the Company effects a two-for-one
forward split of the Common Stock, wherein each issued and outstanding share of Common Stock is converted into two shares of Common Stock,
the number of Warrant Shares shall be increased by 100% and the Exercise Price shall be reduced by 50%; and (ii) in the event that the
Company effects a one-for-two reverse split of the Common Stock, wherein each two issued and outstanding shares of Common Stock are converted
into one share of Common Stock, the number of Warrant Shares shall be reduced by 50% and the Exercise Price shall be increased by 100%.

 

(b)
Excluded Transactions. There shall be no right to equitable or other adjustment to the Exercise Price in connection with the issuance
of (a) Common Stock or options issued to employees, officers, consultants or directors of the Company pursuant to any stock or option
plan duly adopted for such purpose, by the Company board of directors including the approval of all independent (non-employee) directors,
(b) securities issuable pursuant to this Warrant or upon the exercise or exchange of or conversion of any Common Stock issued under the
related Securities Purchase Agreement between the parties hereto, provided that such securities have not been amended since the date
of this Warrant to increase the number of such securities or to decrease the Exercise Price, and (c) Common Stock issued pursuant to
acquisitions or strategic transactions, provided that any such issuance shall only be to a Person (or to the equity holders of a Person)
which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business, but shall not include a transaction
in which the Company is issuing securities for the purpose of raising capital or to an entity whose primary business is investing in
securities, (d) securities issued for consideration other than cash pursuant to a merger, consolidation, acquisition, or similar business
combination approved by the Company board of directors, (e) securities issued pursuant to an equipment loan or leasing arrangement, real
property leasing arrangement or debt financing from a bank or similar financial institution approved by the Company board of directors,
and (f) securities with respect to which the holders of the majority of the outstanding principal under the applicable debt instruments
have waived their anti-dilution rights.

 

(c)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a
given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

(d)
Notice to Holder of Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section
3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment
and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

(e)
Voluntary Adjustment By Company. Subject to the rules and regulations of the Trading Market, the Company may at any time during
the term of this Warrant, subject to the prior written consent of the Holder, reduce the then-current Exercise Price to any amount and
for any period of time deemed appropriate by the board of directors of the Company.

 

Section
4.  Transfer of Warrant; Legend.

 

(a)
No Transfer. This Warrant may not be transferred by the Holder to any other person or entity without the prior written approval
of the Company, to be given or withheld in the sole discretion of the Company, and any such attempted transfer in violation of such limitation
shall be null and void and of no force or effect.

 

    	6

    	 

    

 

(b)
Legends. Any legend required by the securities laws of any state to the extent such laws are applicable to the Warrant Shares
represented by the certificate so legend shall be included on any certificates representing the Warrant Shares. Holder also understands
that the Warrant Shares may bear the following or a substantially similar legend:

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED OR QUALIFIED
UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED, OR HYPOTHECATED
UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION ARE NOT REQUIRED. ANY TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE NOT SET FORTH HEREIN.

 

Section
5.  Miscellaneous.

 

(a)
No Rights as Stockholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights,
dividends, or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(f)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a “cashless exercise” pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(f)(i) and Section 2(f)(iii), in no event, shall the Company be required
to net cash settle an exercise of this Warrant.

 

(b)
Loss, Theft, Destruction, or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft, or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.

 

(c)
Entire Agreement. This Warrant (including any recitals hereto) and the Agreement set forth the entire understanding of the Parties
with respect to the subject matter hereof, and shall not be modified or affected by any offer, proposal, statement or representation,
oral or written, made by or for any Party in connection with the negotiation of the terms hereof, and may be modified only by instruments
signed by the Company and the Holder.

 

(d)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken, or such right may be exercised on the next succeeding Business
Day.

 

    	7

    	 

    

 

(e)
Notices. All notices under this Warrant shall be in writing. Notices may be served by certified or registered mail, postage paid
with return receipt requested, by private courier, prepaid, by other reliable forms of electronic communication, or personally. Mailed
notices shall be deemed delivered five (5) days after mailing, properly addressed. Couriered notices shall be deemed delivered on the
date that the courier warrants that delivery will occur. Electronic communication notices shall be deemed delivered when receipt is either
confirmed by confirming transmission equipment or acknowledged by the addressee or its office. Personal delivery shall be effective when
accomplished. Any Party may change its address by giving notice, in writing, stating its new address to the other Party. Subject to the
foregoing, notices shall be sent as follows:

 

If
to the Company:

 

Nutralife
Biosciences, Inc.

Attn:
Edgar Ward

6601
Lyons Road, Suite L-6

Coconut
Creek, FL 33073

Email:
edgar@nutralifebiosciences.com

 

With
a copy, which shall not constitute notice, to:

 

Anthony
L.G., PLLC

Attn:
Michael R. Geroe

625
N. Flagler Drive, Suite 600

West
Palm Beach, FL 33401

Email:
mgeroe@anthonypllc.com

 

If
to Holder, to the address of Holder as set forth in the Agreement.

 

(f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

(g)
No Waiver. No waiver of any provision of this Warrant shall be effective unless it is in writing and signed by the Party against
whom it is asserted, and any such written waiver shall only be applicable to the specific instance to which it relates and shall not
be deemed to be a continuing or future waiver.

 

(h)
Headings. The article and section headings contained in this Warrant are inserted for convenience only and shall not affect in
any way the meaning or interpretation of the Warrant.

 

(i)
Governing Law. This Warrant, and any dispute arising out of, relating to, or in connection with this Warrant, shall be governed
by and construed in accordance with the laws of the State of Florida, without giving effect to any choice or conflict of law provision
or rule (whether of the State of Florida or of any other jurisdiction) that would cause the application of the laws of any jurisdiction
other than the State of Florida.

 

    	8

    	 

    

 

(j)
Enforcement of the Warrant; Jurisdiction; No Jury Trial.

 

		(i)	Each
                                            of the Parties irrevocably agrees that any legal action or proceeding with respect to this
                                            Warrant and the rights and obligations arising under this Warrant, or for recognition and
                                            enforcement of any judgment or arbitral award or resolution in respect of this Warrant, shall
                                            be brought and determined exclusively in the courts of the State of Florida located in Broward
                                            County, Florida or in the event (but only in the event) that such courts do not have subject
                                            matter jurisdiction over such action or proceeding, in the United States District Court sitting
                                            in Broward County, Florida (the “Selected Courts”). Each of the Parties hereby
                                            irrevocably submits with regard to any such action or proceeding for itself and in respect
                                            of its property, generally and unconditionally, to the personal jurisdiction of the Selected
                                            Courts and agrees that it will not bring any action relating to this Warrant or any of the
                                            transactions contemplated by this Warrant in any court other than the Selected Courts. Each
                                            of the Parties hereby irrevocably waives and agrees not to assert, by way of motion, as a
                                            defense, counterclaim, or otherwise, in any action or proceeding with respect to this Warrant,
                                            (a) any claim that it is not personally subject to the jurisdiction of the Selected Courts
                                            for any reason other than the failure to serve in accordance with the provisions of this
                                            Warrant; (b) any claim that it or its property is exempt or immune from the jurisdiction
                                            of any such court or from any legal process commenced in such courts (whether through service
                                            of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution
                                            of a judgment or otherwise); and (c) to the fullest extent permitted by law, any claim that
                                            (i) the suit, action or proceeding in such court is brought in an inconvenient forum; (ii)
                                            the venue of such suit, action or proceeding is improper; or (iii) this Warrant, or the subject
                                            matter of this Warrant, may not be enforced in or by the Selected Courts.
	 	 	 
		(ii)	EACH
                                            PARTY TO THIS WARRANT HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT
                                            PERMITTED BY LAW, ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY SUIT,
                                            ACTION OR OTHER PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER, RELATING TO OR IN
                                            CONNECTION WITH THIS WARRANT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT.
	 	 	 
		(iii)	The
                                            Holder hereby expressly acknowledges that the agreements and restrictions contained herein
                                            are reasonable and necessary to protect the Company’s legitimate interests, that the
                                            Company would not have entered into this Warrant in the absence of such agreements and restrictions,
                                            and that any violation of such restrictions will result in irreparable harm to the Company.
                                            The Holder agrees that the Company shall be entitled to preliminary and permanent injunctive
                                            relief, without the necessity of proving actual damages and specific performance of, as well
                                            as an equitable accounting of all earnings, profits, and other benefits arising from any
                                            violation of, the agreements and restrictions contained herein, which rights shall be cumulative
                                            and in addition to any other rights or remedies to which the Company may be entitled. The
                                            Holder irrevocably and unconditionally (i) agrees that any legal proceeding arising out of
                                            this Warrant may be brought in the Selected Courts, (ii) consents to the non-exclusive jurisdiction
                                            of the Selected Courts in any such proceeding, and (iii) waives any objection to the laying
                                            of venue of any such proceeding in any Selected Court.

 

    	9

    	 

    

 

(k)
Attorneys’ Fees. If any Party hereto is required to engage in litigation against any other Party, either as plaintiff or
as defendant, in order to enforce or defend any rights under this Warrant, and such litigation results in a final judgment in favor of
such Party (“Prevailing Party”), then the party or parties against whom said final judgment is obtained shall reimburse the
Prevailing Party for all direct, indirect or incidental expenses incurred, including, but not limited to, all attorneys’ fees,
court costs and other expenses incurred throughout all negotiations, trials or appeals undertaken in order to enforce the Prevailing
Party’s rights hereunder.

 

(l)
Parties in Interest. This Warrant shall be binding upon and inure solely to the benefit of each Party, and nothing in this Warrant,
express or implied, is intended to confer upon any other person or entity any rights or remedies of any nature under or by reason of
this Warrant.

 

(m)
Severability; Expenses; Further Assurances. If any term, condition, or other provision of this Warrant is determined by a court
of competent jurisdiction to be invalid, illegal or incapable of being enforced by any rule of law or public policy, all other terms,
conditions, and provisions of this Warrant shall nevertheless remain in full force and effect so long as the economic or legal substance
of the transactions contemplated by this Warrant is not affected in any manner materially adverse to any Party. Upon such determination
that any term or other provision is invalid, illegal, or incapable of being enforced, the Parties shall negotiate in good faith to modify
this Warrant so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that
the transactions contemplated by this Warrant be consummated as originally contemplated to the fullest extent possible. Except as otherwise
specifically provided in this Warrant, each Party shall be responsible for the expenses it may incur in connection with the negotiation,
preparation, execution, delivery, performance, and enforcement of this Warrant. The Parties shall, from time to time, do and perform
any additional acts and execute and deliver any additional documents and instruments that may be required by Law or reasonably requested
by any Party to establish, maintain or protect its rights and remedies under, or to effect the intents and purposes of, this Warrant.

 

(n)
Execution in Counterparts, Electronic Transmission. This Warrant may be executed in any number of counterparts, each of which
shall be deemed an original. The signature of any Party which is transmitted by any reliable electronic means such as, but not limited
to, a photocopy, electronically scanned or facsimile machine, for purposes hereof, is to be considered as an original signature, and
the document transmitted is to be considered to have the same binding effect as an original signature or an original document.

 

(o)
Currency. All dollar amounts are in U.S. dollars.

 

********************

 

(Signature
Page Follows)

 

    	10

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the Issue Date.

 

	 	Nutralife
    Biosciences, Inc.
	 	 	 
	 	By:	/s/
    Edgar Ward
	 	Name:	Edgar
    Ward
	 	Title:	Chief
    Executive Officer

 

	Agreed
    and accepted:	 
	 	 	 
	INVESTOR:
    GREEN DYNAMICS, LLC	 
	 	 	 
	BY
    FAM COR ENTERPRISES, LLC	 
	 	 	 
	By:	/s/
    Mitchell Pasin	 
	Name:	Mitchell
    Pasin	 
	Title:
    	Managing
    Member	 

 

    	11

    	 

    

 

NOTICE
OF EXERCISE

 

	TO:	Nutralife
    Biosciences, Inc.

 

(1)
The undersigned hereby elects to purchase ______________Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2)
Payment shall take the form of (check applicable box):

 

	 	☐	in lawful money of the United States; or

 

	 	☐	if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in Section 2(c) of the attached Warrant, to exercise this Warrant with respect
to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in such in Section 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 	 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

	 	 
	 	 
	 	 

 

	Name
    of Holder:	 
	 	 	 
	 	 	 
	By:	 	 
	Name:
    	 	 
	Title:	 	 
	 	 	 
	Date:	____          202	 

 

    	12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]